BiotechTube
Home/Pipeline/Lead ADC Program (Pancreatic Cancer)

Lead ADC Program (Pancreatic Cancer)

Pancreatic Cancer

Pre-clinicalActive

Key Facts

Indication
Pancreatic Cancer
Phase
Pre-clinical
Status
Active
Company
Medicovestor

About Medicovestor

Medicovestor is a private, preclinical-stage biotech developing a next-generation ADC platform designed to combine targeted cytotoxicity with potent immune system activation. The company is targeting pancreatic and ovarian cancers, two areas with high unmet medical need and notoriously difficult to treat. Its approach aims to improve upon current ADC therapies by engaging the immune system to create a more durable anti-tumor response. As a pre-revenue entity, its success hinges on validating its platform in the clinic and securing strategic partnerships or further funding.

View full company profile

Therapeutic Areas

OncologyPancreatic CancerOvarian Cancer

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
AHPBA IRE RegistryAngioDynamicsPost-Market Registry
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b